ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, developing novel treatments for kidney, cardiovascular and liver disorders. Its lead product candidate, ZS-9, is a novel investigational treatment for hyperkalemia being evaluated in late-stage clinical trials to remove excess potassium and maintain normal potassium levels. The company recently completed a 753-patient Phase 3 study showing ZS-9 rapidly reduced serum potassium to normal within 48 hours and maintained potassium with once-daily dosing, with an adverse event profile similar to placebo. ZS Pharma plans to initiate two additional studies in 2014 and intends to file an NDA with the FDA and an MAA with the EMA in early 2015. The company is also pursuing additional drug candidates that utilize its selective ion-trap technology for kidney and liver diseases. Proceeds from the recent financing will be used to advance ZS-9 through NDA and MAA submissions. ZS Pharma develops ZS-9, a crystal form of zirconium silicate designed to remove life-threatening toxins from patients with kidney and liver disease. Initial human clinical testing targeted patients with elevated blood potassium (hyperkalemia). The company intends to advance ZS-9 through pivotal trials and prepare for commercialization. It also plans to research and develop additional compounds targeting kidney and liver conditions with limited treatment options. ZS Pharma is led by president and CEO Dr. Al Guillem and is based in Fort Worth, Texas. The company closed a $46M financing to fund development and pivotal trials.

Total raised

$101M

Funding rounds

2

Latest round

Series D

Latest activity

Mar 2014